Skip to main content
Fig. 2 | BMC Gastroenterology

Fig. 2

From: Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients

Fig. 2

Change of HBV DNA in HBeAg-positive patients. a The mean reduction in serum hepatitis B virus (HBV) DNA levels from baseline to month 12 was similar in tenofovir and entecavir group (−5.88 vs. −5.54 log10 IU/mL, P = 0.159) in the hepatitis e antigen (HBeAg) positive patients. b Serum HBV DNA levels were more strongly suppressed by tenofovir than entecavir (−5.92 vs. −5.78 log10 IU/mL, P = 0.022) in the HBeAg-positive patients with a higher HBV DNA levels

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us